Franklin Street Advisors Inc. NC Raises Holdings in AbbVie Inc. $ABBV

Franklin Street Advisors Inc. NC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 2.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 182,921 shares of the company’s stock after acquiring an additional 4,257 shares during the period. AbbVie accounts for approximately 2.4% of Franklin Street Advisors Inc. NC’s portfolio, making the stock its 12th biggest position. Franklin Street Advisors Inc. NC’s holdings in AbbVie were worth $41,796,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ABBV. Vanguard Group Inc. increased its holdings in shares of AbbVie by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock valued at $41,155,601,000 after acquiring an additional 448,554 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of AbbVie by 4.3% in the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after acquiring an additional 493,420 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares during the last quarter. Amundi increased its holdings in shares of AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after acquiring an additional 1,414,621 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of AbbVie by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock valued at $2,241,363,000 after acquiring an additional 408,426 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 2.6%

AbbVie stock opened at $211.74 on Thursday. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock has a 50 day moving average of $220.80 and a two-hundred day moving average of $224.19. The stock has a market capitalization of $374.40 billion, a price-to-earnings ratio of 89.72, a PEG ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period last year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie filed a lawsuit seeking clearer, narrower guidance on which patients qualify for a federal drug discount program — a step that could limit discount exposure and protect revenue/margins if the court or settlement tightens eligibility. AbbVie files lawsuit to address ‘outdated’ drug discount eligibility program
• Positive Sentiment: New dermatology data showcased at the AAD meeting (Skyrizi and Rinvoq long‑term outcomes, safety and expanded labels) support AbbVie’s immunology growth thesis and help de‑risk revenue concentration away from Humira. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
• Positive Sentiment: Analyst support and dividend/cash‑flow strength: recent analyst notes (including high price targets from JPMorgan and an overweight stance from Cantor Fitzgerald despite a modest PT trim) plus strong free cash flow and a reliable dividend underpin investor confidence. AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns Cantor Fitzgerald lowers price target to $240, remains Overweight
• Neutral Sentiment: Broader health-care sector strength lifted stocks broadly today, providing a tailwind to ABBV alongside company‑specific news. Sector Update: Health Care Stocks Advance in Afternoon Trading
• Neutral Sentiment: Market commentary and trending coverage (Zacks, Seeking Alpha) are spotlighting AbbVie’s pipeline and dividend, keeping the name on investor radars but not adding new hard catalysts. AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: AbbVie added Humira to the TrumpRx program at a steep (reported ~86%) discount for broader access — a move that could pressure Humira residual revenues and overall pricing power in the U.S. over time. Humira’s TrumpRx Discount Raises New Questions For AbbVie Valuation
• Negative Sentiment: Valuation and guidance risks remain: some analysts and commentators flag that recent volatility, competitive pressures and any guidance softness could limit upside despite strong drug growth — a caution that can weigh on the stock if sentiment flips. Why The AbbVie (ABBV) Story Is Shifting As Immunology Hopes Meet Valuation Doubts

Analysts Set New Price Targets

A number of research firms have recently commented on ABBV. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. William Blair reiterated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a report on Wednesday, January 28th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $252.65.

Insider Activity at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.25% of the stock is owned by company insiders.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.